InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | 2026-04-03 | Hoffman Michael B | Director | Purchase | 713.8K | $2.10 | $1.50M | 3.29M | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | $25.2M+26.1% | $20.0M-48.5% | $38.8M+134.9% | $16.5M |
| General and administrative | $4.5M-33.1% | $6.7M+7.3% | $6.2M-30.6% | $9.0M |
| Total operating expenses | $29.7M+11.2% | $26.7M-40.7% | $45.0M+76.5% | $25.5M |
| Operating loss | -$29.7M-11.2% | -$26.7M+40.7% | -$45.0M-76.5% | -$25.5M |
| Interest income | $699K+110.7% | $332K-50.3% | $668K+265.5% | $183K |
| Other financing costs | -$1.9M | — | — | — |
| Change in fair value of warrants | $142K-96.1% | $3.6M+130.6% | -$11.8M | — |
| Total other income, net | $841K-60.0% | $2.1M | — | — |
| Net loss | -$28.9M-17.3% | -$24.6M+56.2% | -$56.2M-121.9% | -$25.3M |
| Basic (dollars per share) | -$1.4+30.7% | -$2.02+67.6% | -$6.23 | — |
| Diluted (dollars per share) | -$1.4+39.4% | -$2.31+62.9% | -$6.23 | — |
| Basic | $20.6M+68.7% | $12.2M+35.0% | $9.0M | — |
| Diluted | $20.6M+68.0% | $12.2M+35.6% | $9.0M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants